Evidence map›Paper›PMID 34199975›Full record

ReviewCells2021

Inflammation during Percutaneous Coronary Intervention-Prognostic Value, Mechanisms and Therapeutic Targets.

Bradley Tucker, Kaivan Vaidya, Blake J Cochran, Sanjay Patel

2 registry-linked trialsOpen access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Cells, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 42 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
42citing papers in PubMed, 3 pooled it
4.6field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05860400 recruitingnot on this mapstarted 2023, after this paper: background citation

Efficacy and Safety of Comprehensive Treatment in Patients With Inflammation-associated Rapidly-progressive Coronary Artery Disease (IR-CAD): a Self-controlled Cohort Study

Typeobservational_patient_registrySponsorPeking Union Medical College HospitalRan2023 to 2026Enrolled39ConditionsCoronary Artery Disease, Coronary Artery Stenosis, Coronary Artery Restenosis, Coronary Artery Disease ProgressionArmsHealthy life style, Secondary prevention for atherosclerotic coronary artery disease, Immunosuppressive therapy, Coronary revascularization, Supportive therapies
NCT06007248 recruitingnot on this mapstarted 2023, after this paper: background citation

Disease Characteristics of Inflammation-associated Rapidly-progressive Coronary Artery Disease (IR-CAD): a Case-control Study

TypeobservationalSponsorPeking Union Medical College HospitalRan2023 to 2026Enrolled30ConditionsCoronary Artery Disease, Coronary Artery Stenosis, Coronary Artery Restenosis, Coronary Artery Disease ProgressionArmsProtocol-defined Examinations
3 · Its place in the literature

Who cites it

42 citing papers in PubMed, 3 syntheses or guidelines pooled it, 45 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Article
  5. Review
  6. Review
  7. Article
  8. Review
  9. Article
  10. Observational
  11. Article
  12. Review
  13. Article
  14. The role of IL-6 in atherosclerosis: a narrative review.Frontiers in cardiovascular medicine · 2026
    Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Bradley TuckerHeart Research Institute, 7 Eliza St., Newtown 2042, Australia.ORCID 0000-0002-7028-4331
Kaivan VaidyaSydney Medical School, University of Sydney, Camperdown 2050, Australia.
Blake J CochranSchool of Medical Sciences, University of New South Wales, Kensington 2052, Australia.ORCID 0000-0002-9615-7939
Sanjay PatelHeart Research Institute, 7 Eliza St., Newtown 2042, Australia.
The University of Sydney · AUUNSW Sydney · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Periprocedural myocardial injury and myocardial infarction (MI) are not infrequent complications of percutaneous coronary intervention (PCI) and are associated with greater short- and long-term mortality. There is an abundance of preclinical and observational data demonstrating that high levels of pre-, intra- and post-procedural inflammation are associated with a higher incidence of periprocedural myonecrosis as well as future ischaemic events, heart failure hospitalisations and cardiac-related mortality. Beyond inflammation associated with the underlying coronary pathology, PCI itself elicits an acute inflammatory response. PCI-induced inflammation is driven by a combination of direct endothelial damage, liberation of intra-plaque proinflammatory debris and reperfusion injury. Therefore, anti-inflammatory medications, such as colchicine, may provide a novel means of improving PCI outcomes in both the short- and long-term. This review summarises periprocedural MI epidemiology and pathophysiology, evaluates the prognostic value of pre-, intra- and post-procedural inflammation, dissects the mechanisms involved in the acute inflammatory response to PCI and discusses the potential for periprocedural anti-inflammatory treatment.

Indexed as

Endothelium, VascularMyocardial InfarctionPostoperative ComplicationsHumansIncidenceInflammationPercutaneous Coronary InterventionPrognosisangioplastyatherosclerosiscardiovascular diseaseinflammationmyocardial infarctionpercutaneous coronary interventionperiprocedural myocardial infarction

Identifiers

PMID34199975
PMCPMC8230292
OpenAlexW3171630602

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.